King Pharmaceuticals KG AmTrust Reinsurance legacy business — Reinsurance recoverables on unpaid losses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ReinsuranceRecoverablesOnUnpaidLossesGross.
The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about King Pharmaceuticals's amtrust reinsurance legacy business — reinsurance recoverables on unpaid losses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is King Pharmaceuticals's amtrust reinsurance legacy business — reinsurance recoverables on unpaid losses?
- King Pharmaceuticals (KG) reported amtrust reinsurance legacy business — reinsurance recoverables on unpaid losses of $403.04M in Q1 2026.
- What does amtrust reinsurance legacy business — reinsurance recoverables on unpaid losses mean?
- This metric measures the total amount of unpaid losses that the company expects to recover from reinsurers for the legacy reinsurance business segment. It represents the asset side of reinsurance contracts, reflecting the portion of claims liabilities that are ceded to other insurance entities. This figure is a critical indicator of the company's reliance on reinsurance partners to mitigate insurance risk.